Increase in unbound apo(a) with muvalaplin not linked to cardiovascular or kidney biomarker changes

Increased levels of unbound apo(a) which occur with muvalaplin treatment are not correlated with changes in biomarkers of cardiovascular or kidney disease. This is the main finding from a post hoc analysis of data from a Phase 2 trial of muvalaplin, an Lp(a) lowering agent in development that, in contrast to other Lp(a) targeting agents, is designed to block binding of apo(a) to apoB, thereby preventing Lp(a) formation.